Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice

1 Jan 2021

Abstract excerpt

Background & Aims Intrahepatic cholangiocarcinoma (iCCA) accounts for a fraction of primary liver cancers but has a 5-year survival rate of only 10%. Immune checkpoint inhibitors are effective in treating many solid cancers, but immune checkpoint inhibitor monotherapy has no clear benefit in iCCA. Mitogen-activated kinase (MEK) inhibitors, such as trametinib, have shown promising results in preclinical studies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Liver Diseases and Immunity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34033968
DOI: 10.1016/j.jcmgh.2021.05.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in MicePMID 34033968Read ↗

DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01.Semantic proximity Read ↗

Molecular Subtypes and Precision Oncology in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

The Immune–Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel ImmunotherapiesSemantic proximity Read ↗

Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responsesSemantic proximity Read ↗

TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Identification of Transcriptional Regulators of Immune Evasion across Cancers: An Alternative Immunotherapeutic Strategy for CholangiocarcinomaSemantic proximity Read ↗

Genetic/Epigenetic Alteration and Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Transforming the Immune Microenvironment with Molecular-Targeted AgentsSemantic proximity Read ↗

TIGIT drives the immunosuppressive environment by downregulation of metalloproteinases MMP2 and MMP14 in perihilar cholangiocarcinomaSemantic proximity Read ↗

Immunogenomics of cholangiocarcinomaSemantic proximity Read ↗

M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

A Novel PI3K-driven Mouse Model of Intrahepatic Cholangiocarcinoma and Synergistic Antitumor Effects of Combined PI3K and WEE1 InhibitionSemantic proximity Read ↗

INTS8 Predicts a Therapeutic Target for Intrahepatic Cholangiocarcinoma via Integration of Bioinformation Analysis and Experimental ValidationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.